Build vs. Connect: The Collection Infrastructure Decision Every Specialty Lab Has to Make

Every growing specialty lab reaches this question eventually.

Do we build our own collection infrastructure — develop direct draw site relationships market by market, hire collection operations staff, build the compliance and training systems that qualified draw partners require? Or do we connect to a network that has already done it?

It sounds like a genuine fork in the road. In practice, for most specialty labs, it's not a close call — and the labs that have tried to build discover why fairly quickly.

This blog is an honest look at what building a network actually costs, what it requires from a compliance standpoint, and why connecting to the MOMS MAP: Medical Access Point/Provider™ network consistently produces better outcomes for specialty labs at a fraction of the operational investment.

What "building your own network" actually means

Building isn't a decision. It's a commitment to running a second operational function alongside your core lab business — indefinitely.

Here's what that commitment looks like in practice:

Market-by-market sourcing

Every geography you want to serve requires identifying qualified draw site candidates, evaluating their capability against your test requirements, negotiating terms, and bringing them into your operational process. In dense metro markets with established phlebotomy workforces, this is difficult. In rural and semi-rural markets — where specialty lab patients increasingly live — it can take months, and the result may be a single-partner dependency that leaves you exposed if anything changes.

Credentialing and verification

Every draw site partner your lab uses must be credentialed. State licensure, phlebotomy certification, current insurance — each requires verification at onboarding and periodic re-verification throughout the relationship. For a lab with draw site partners in 20 or 30 markets, this is a continuous administrative workload that requires dedicated staff and organized documentation systems.

If a partner's license lapses and you don't catch it, the exposure is yours.

HIPAA compliance infrastructure

Every draw site handling patient health information on behalf of your lab must operate under a Business Associate Agreement (BAA) and meet HIPAA compliance standards. Establishing that framework with each partner, auditing their practices, and maintaining documentation of compliance is your lab's responsibility — not the draw site's.

Most small independent draw sites don't have dedicated compliance staff. Your lab is effectively providing compliance infrastructure for every partner you bring into the network.

Training — built and maintained by you

Your test's specific collection requirements — tube types, draw order, chain of custody documentation, temperature handling, deviation reporting — don't exist in a standard phlebotomy curriculum. You have to build the training materials, deliver them to each draw site partner, and update them every time your collection protocol changes or a new test enters the portfolio.

This is not a one-time investment. Every new partner onboarded, every test added, every protocol updated requires the training cycle to run again — across every draw site in your network.

Ongoing operational management

Draw sites lose phlebotomists. Licenses lapse. Partners exit markets. Kit delivery windows get missed. Deviations happen and don't get reported. Managing a collection network means managing all of these things continuously — with the operational bandwidth to respond quickly when something breaks, in a market you may not have alternative coverage for.

Building your own collection network means your lab is now in the collection network operations business. That is a full-time function — and it's not why your lab exists.

The compliance burden is larger than most labs expect

The regulatory requirements around specimen collection are not static, and the liability for compliance failures sits with the lab, not the draw site.

State phlebotomy licensure requirements vary — and change. Some states require specific continuing education for license renewal. Others have recently updated certification requirements. Tracking those changes across a multi-state draw site network and ensuring every partner remains compliant is an ongoing legal and compliance obligation.

Chain of custody documentation requirements are evolving. Payers in the oncology and genetic testing space increasingly require documented COC as a condition of reimbursement. When a claim gets denied because a draw site's documentation was incomplete, the denial hits the lab's billing — even though the failure occurred at a partner site the lab may have limited visibility into.

Business Associate Agreements (BAAs) must be executed with every HIPAA-covered draw site and maintained accurately. A gap in BAA coverage — even with a partner you've worked with for years — creates legal exposure.

In a self-built network, every compliance failure at a draw site is your lab's compliance failure. MOMS absorbs that liability by maintaining compliance infrastructure for every MAP in the network.

What connecting to MOMS actually costs — and what it buys

Connecting to MAPs on the MOMS network replaces the operational and compliance burden described above in a single platform relationship. Here's the direct comparison:

The cost comparison isn't just about dollars spent — it's about where your team's time and attention goes. Every hour spent sourcing draw site partners, building training materials, verifying credentials, and managing compliance documentation is an hour not spent on the science, the clinical relationships, and the commercial execution that differentiate your lab in the market.

The geographic reach you can't replicate by building

The MAP: Medical Access Point/Provider™ network has coverage across all 50 states and the top 100 metropolitan statistical areas — including geographic coverage in rural and semi-rural markets that most draw networks don't reach.

Building equivalent coverage independently isn't a matter of budget. It's a matter of time and market reality. In many non-metro geographies, the phlebotomy workforce is thin enough that sourcing a qualified draw site partner takes months — if candidates exist at all. MOMS has already done, and continues doing, that work.

When a specialty lab joins MOMS, geographic coverage in markets they've never operated in is immediately available. A test launching into a new region doesn't require a parallel six-month draw site sourcing initiative. The network is there.

For specialty labs whose patients are geographically distributed — which describes most specialty test categories — that reach isn't a nice-to-have. It's the difference between a test that works nationally and one that works in markets the lab happened to have already built relationships in.

The compliance infrastructure MOMS provides — built in

Every MAP in the MOMS network goes through a compliance onboarding process before their first draw. That process covers:

• Credential verification — state licensure or certification confirmed and documented

• Business Associate Agreement execution — HIPAA coverage established before any patient health information is handled

• Collection protocol training — specific to the test being performed and the lab's requirements
  

When a specialty lab's collection requirements change — new test added, updated kit protocol, revised standards — the MAP can see the changes and are trained accordingly. The lab provides the protocol. MOMS executes the training. With the implementation of Sticklogistics®, a MOMS-powered LMS, labs can create training modules that the MAPs must complete prior to performing collections for patients.

This means the compliance infrastructure that would cost a self-building lab significant staff time and ongoing management attention is included in the platform relationship. It runs in the background. The lab's team focuses elsewhere.

Why utilizing MOMS is the cost-effective choice

There are theoretical conditions under which building a direct collection network might make economic sense: a lab with very high draw volume locked into a single metro market, or a test with collection requirements so proprietary that no existing network has been trained for them. In practice, neither scenario describes the reality of most specialty labs — and the labs that have tested the build path have learned its cost the hard way.

The conclusion they consistently reach: the operational overhead is higher than projected, the compliance burden is larger than anticipated, and the geographic gaps that appear when a draw site partner exits a market are harder to fill than expected. What looked like a cost-saving decision at the outset becomes an ongoing investment in infrastructure that diverts time, budget, and leadership attention away from the lab's core business.

MOMS doesn't just solve the problems of building your own network. It removes them from the equation entirely — at a cost that consistently outperforms the build alternative.

The cost math is straightforward

Building a direct collection network requires your lab to absorb every cost that MOMS has already paid at scale: draw site sourcing staff time, credentialing infrastructure, HIPAA compliance overhead, training development and delivery, chain of custody protocol enforcement, and ongoing partner management. Those costs don't appear on a single line item — they distribute across your operations team, your legal and compliance function, and your lab leadership calendar.

Connecting to MOMS replaces that distributed cost with a single platform relationship. The network infrastructure — already built, already compliant, already geographically deployed — is available immediately. You pay for access to a national collection network that took years to build, not the cost of building one yourself.

For specialty labs doing the honest math: the per-draw cost of connecting to MOMS, when measured against the fully loaded cost of operating a self-built network at comparable scale and geographic reach, consistently favors utilizing the MOMS platform. The margin widens further when you account for the cost of compliance failures, draw site attrition, and the management overhead that self-built networks require indefinitely.

Compliance is included — not your problem to solve

The compliance burden of a self-built collection network doesn't scale linearly with the number of draw site partners — it compounds. Each new partner adds credentialing verification, BAA execution, compliance auditing, and training documentation to your ongoing workload. Each state you operate in adds a licensure monitoring obligation. Each protocol update requires a re-training cycle across every partner in the network.

MOMS absorbs all of it. Every MAP is required to be licensed, insured, have medical oversight and not be on the OIG exclusion list. Every MAP operates under the MOMS compliance framework. BAAs are handled at the platform level. When your collection protocol changes, MOMS communicates it to the network and MAPs are able to see the updated instructions in real-time.

Your lab provides the test protocol. MOMS handles the infrastructure that puts it into practice. That's not a minor operational benefit — for a specialty lab trying to scale nationally without building a compliance team to match, it's often the deciding factor.

Specialty labs utilizing MOMS aren't outsourcing their collection infrastructure. They're accessing infrastructure that already exists — at lower cost, with compliance built in, and with the geographic reach to serve their patients wherever they live.

The bottom line

The build vs. connect question sounds strategic. In practice, it usually resolves quickly once the full cost of building — in staff time, compliance infrastructure, geographic limitations, and operational fragility — is laid against the cost of connecting to a network that has already solved those problems at scale.

MOMS was built as The Connection for the Collection® — the layer that specialty labs need: national geographic reach, compliance infrastructure built in, test-specific MAP training handled at the platform level, and the operational resilience that comes from a network rather than a set of bilateral draw site relationships.

The specialty labs that connect early don't just save the operational cost of building. They redirect that attention toward what actually differentiates them — and they grow into markets their competitors are still trying to source draw sites in.